Analytical Data
-
Gene name
TCIRG1
- Application
-
Alternative Names
Stv1; Vph1; ATP6N1C; ATP6V0A3; Atp6i; OC-116kDa; OC116; OPTB1; TIRC7; a3; V-Type Proton ATPase 116 kDa Subunit A Isoform 3; Osteoclastic proton pump 116 kDa subunit
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13488
-
Expression Region
Arg49~Val348
-
Molecular Weight
38kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TCIRG1, or T-cell immune regulator 1, plays a critical role in the immune system by regulating the function of T cells, which are essential for adaptive immunity. Mutations in the TCIRG1 gene are linked to autosomal recessive osteopetrosis, a disorder characterized by excessive bone density due to impaired osteoclast function. This has garnered significant interest in the research community, as understanding the mechanisms governing TCIRG1 can provide insights into both bone metabolism and immune regulation. The recombinant protein form of TCIRG1 has been studied for its potential therapeutic applications, particularly in bone disorders and immune-related diseases. Research has focused on elucidating the structural and functional properties of the TCIRG1 protein, which may aid in the development of gene therapies or protein replacement strategies for affected individuals. Additionally, TCIRG1 serves as a valuable model for exploring the intricate interplay between the immune system and bone health, offering promising avenues for innovative treatments in both fields.
